Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2022

22.12.2021 | short review

Practice-changing strategies in the treatment of esophageal cancer

verfasst von: Ercan Müldür, MD, Wolfgang Hilbe, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Summary

For patients suffering from localized and advanced stage esophageal cancer, long-term outcomes remain poor. However, as already seen in other tumors, the introduction of immune checkpoint inhibitors has led to practice-changing results in the treatment of esophageal cancer. In this short review, five emerging studies are presented and discussed, which have changed standard of care in this disease.
Literatur
1.
Zurück zum Zitat Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2.
Zurück zum Zitat International Agency for Research on Cancer, WHO. Globocan. China. 2020. International Agency for Research on Cancer, WHO. Globocan. China. 2020.
3.
Zurück zum Zitat Arnold M, et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69(9):1564–71. CrossRef Arnold M, et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69(9):1564–71. CrossRef
4.
Zurück zum Zitat Hou H, et al. Survival of esophageal cancer in China: a pooled analysis on hospital-based studies from 2000 to 2018. Front Oncol. 2019;9:548. CrossRef Hou H, et al. Survival of esophageal cancer in China: a pooled analysis on hospital-based studies from 2000 to 2018. Front Oncol. 2019;9:548. CrossRef
5.
Zurück zum Zitat van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84. CrossRef van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84. CrossRef
6.
Zurück zum Zitat Sjoquist KM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy forresectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. CrossRef Sjoquist KM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy forresectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. CrossRef
7.
Zurück zum Zitat Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–1195. CrossRef Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–1195. CrossRef
8.
Zurück zum Zitat Kelly RJ, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): first results of the checkmate 577 study. Ann Oncol. 2020;31(4):S1142–S215. Kelly RJ, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): first results of the checkmate 577 study. Ann Oncol. 2020;31(4):S1142–S215.
9.
Zurück zum Zitat Kato K, Sun J, Shah MA. Pembrolizumab plus chemotherapy versus chemotherapy as first line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31(4):S1142–S215. Kato K, Sun J, Shah MA. Pembrolizumab plus chemotherapy versus chemotherapy as first line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31(4):S1142–S215.
10.
Zurück zum Zitat Chau I, Doki Y, Ajani JA, et al. Nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: first results of the checkmate 648 study. 2021 ASCO Annual Meeting. 2021. Abstract 4001. Chau I, Doki Y, Ajani JA, et al. Nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: first results of the checkmate 648 study. 2021 ASCO Annual Meeting. 2021. Abstract 4001.
11.
Zurück zum Zitat Kojima T, Shah MA, Muro K, et al. KEYNOTE-181 investigators. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–48. CrossRef Kojima T, Shah MA, Muro K, et al. KEYNOTE-181 investigators. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–48. CrossRef
12.
Zurück zum Zitat Kato K, Cho B, Takahashi M, Okada M, Lin C, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase III trial. Lancet Oncol. 2019;20:1506–17. CrossRef Kato K, Cho B, Takahashi M, Okada M, Lin C, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase III trial. Lancet Oncol. 2019;20:1506–17. CrossRef
14.
Zurück zum Zitat Shen L, Lu Z‑H, Wang J‑Y, et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastaticesophageal squamous cell cancer: first results of the phase III ORIENT-15 study. European Society for Medical Oncology Congress; September 16–21, 2021. 2021. Abstract LBA52. Shen L, Lu Z‑H, Wang J‑Y, et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastaticesophageal squamous cell cancer: first results of the phase III ORIENT-15 study. European Society for Medical Oncology Congress; September 16–21, 2021. 2021. Abstract LBA52.
15.
Zurück zum Zitat Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric orgastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT- 16: first results of a randomized, double-blind,phase III study. European Society for Medical Oncology Congress; September 16–21, 2021. 2021. Abstract LBA53. Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric orgastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT- 16: first results of a randomized, double-blind,phase III study. European Society for Medical Oncology Congress; September 16–21, 2021. 2021. Abstract LBA53.
Metadaten
Titel
Practice-changing strategies in the treatment of esophageal cancer
verfasst von
Ercan Müldür, MD
Wolfgang Hilbe, MD
Publikationsdatum
22.12.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00779-1

Weitere Artikel der Ausgabe 1/2022

memo - Magazine of European Medical Oncology 1/2022 Zur Ausgabe